Phase 2 Trial of Irofulven to Treat Metastatic Castration-Resistant Prostate Cancer Opens in Denmark

Phase 2 Trial of Irofulven to Treat Metastatic Castration-Resistant Prostate Cancer Opens in Denmark
Oncology Venture announced that patient enrollment has begun in a Phase 2 study evaluating irofulven as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC). Specifically, the trial  (NCT03643107) is for patients who failed to respond to one or two prior androgen receptor-targeted therapies – including Zytiga (abiraterone acetate) and Xtandi (enzalutamide) – and to Taxotere (docetaxel) for

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *